Introduction {#s0001}
============

Non-small-cell lung cancer (NSCLC) represents as the most common cancer worldwide. Furthermore, the incidence of NSCLC continues to increase and its mortality rate is high.[@cit0001],[@cit0002] Despite the advancement of NSCLC treatment in recent decades, the 5-year survival rate of NSCLC is still lower than 5%.[@cit0003],[@cit0004] Nowadays, although surgical resection is still the most effective approach for NSCLC treatment, chemotherapy is still indispensable for postoperative adjuvant treatment and treatment of metastatic cancers.[@cit0005],[@cit0006] However, many patients' tumors usually develop obvious drug resistance.[@cit0007],[@cit0008] It is urgent to explore strategies to solve the problem of chemoresistance of NSCLC.

Cisplatin is a major platinum-based anti-tumor drug used for NSCLC treatment.[@cit0009],[@cit0010] Cisplatin is known to induce the formation of intra-strand guanine-guanine and guanine-adenine DNA links in cancer cells. As the results of DNA damage, cisplatin induces apoptotic cell death of cancers.[@cit0011],[@cit0012] Nowadays, cisplatin-based chemotherapy is still used as the first-line treatment for NSCLC.[@cit0013],[@cit0014] However, virtually all of the NSCLC cells eventually become resistant to cisplatin because of the long-term use of it.[@cit0015],[@cit0016] Novel approaches are required to overcome the resistance of cisplatin in NSCLC.

MicroRNAs (miRNAs) are a class of non-coding small RNAs. They are classical gene regulators because they can suppress gene expression through binding to the 3ʹ-untranslated regions (3ʹ-UTR) of targeted genes.[@cit0017]--[@cit0019] Since 60% of the human genes are regulated by miRNAs, miRNAs participate in various physiological processes including cell proliferation, differentiation and apoptosis.[@cit0020],[@cit0021] However, cancer cells including NSCLC cells usually change their expression profile of miRNAs to develop drug resistance.[@cit0022],[@cit0023] Thus, miRNAs are potential targets in chemotherapy.

MicroRNA-140 (miR-140) is reported to function as a tumor suppressor through suppression of cell proliferation, invasion and metastasis in several cancers including gastric cancer, glioma cells and cervical cancer.[@cit0024]--[@cit0026] Furthermore, previous studies have indicated that miR-140 can enhance chemosensitivity of some cancers including NSCLC.[@cit0027]--[@cit0029] On the other hand, patients may benefit from miR-140, because miR-140 can attenuate the acute kidney injury induced by cisplatin through the Nrf2/ARE pathway.[@cit0030] Here, we investigated the effect of miR-140 on reducing the cisplatin-resistance of NSCLC and then explored the potential mechanisms.

Materials and Methods {#s0002}
=====================

Establishment of Cisplatin-Resistant NSCLC Models {#s0002-s2001}
-------------------------------------------------

Human NSCLC cell lines PC9 and A549 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS, Gibco) at 37°C in a humidified incubator with 5% CO~2~. To establish the cisplatin-resistant NSCLC models, we exposed the PC9 and A549 cells with gradually increasing concentrations of cisplatin. Briefly, PC9 and A549 cells were initially treated with 0.2 μM cisplatin for 2 months. Subsequently, the cisplatin concentration was increased by 0.1 μM every 2 weeks up to a final concentration of 2 μM. The established cisplatin-resistant PC9 and A549 cells were named as PC9/R and A549/R, respectively. Furthermore, to eliminate the influence of residual cisplatin in culture medium, the PC9/R and A549/R cells were cultured in cisplatin-free RPMI-1640 medium for 2 weeks prior to the experiments.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) {#s0002-s2002}
----------------------------------------------------------

Relative expression of miR-140 and SIRT1 was detected by qRT-PCR on an Applied Biosystems ABI Prism 7500 sequence detection system (Applied Biosystems, CA, USA). Briefly, total RNAs were isolated from NSCLC cells by using Trizol^®^ reagent (Invitrogen) according to the manufacturer's instruction. For detection of miR-140, cDNA was reverse transcribed by using the One Step PrimeScript miRNA cDNA Synthesis Kit (TaKaRa, Beijing, China). For measurement of SIRT1, cDNA was synthesized by using M-MLV Reverse Transcriptase (Invitrogen). Subsequently, real-time PCR amplification was performed by using SYBR Premix Ex Taq (TaKaRa).

Gain (Loss)-of-Function of MiR-140 and SIRT1 {#s0002-s2003}
--------------------------------------------

To overexpress SIRT1, SIRT1 expression vector was conducted by cloning the open reading frame of SIRT1 gene into the pcDNA3.1 plasmid (Invitrogen, CA, USA). To directly knockdown SIRT1, SIRT1 small interfere RNA (siRNA) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). To overexpress miR-140, miR-140 mimic was purchased from GenePharma Co. Ltd. (Shanghai, China). To knockdown miR-140, miR-140 antisense oligonucleotide (anti-miR-140) was purchased from GenePharma Co. Ltd. To perform the gain (loss)-of-function experiments of miR-140 and SIRT1, cells were transient transfected with miR-140 (50 pmol/mL), anti-miR-140 (50 pmol/mL), SIRT1 plasmid (2 μg/mL) or SIRT1 siRNA (50 pmol/mL) by using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instruction. Negative control oligonucleotides (NCO, Genechem Co., Ltd), empty pcDNA3.1 plasmid and control siRNA were used as internal control.

Cell Viability Detection {#s0002-s2004}
------------------------

Cell Counting Kit-8 (CCK-8) assay was performed to detect the viability of NSCLC cells. Briefly, transfected cells were seeded into 96-well plates at a density of 5×10^3^/well and cultured at 37°C. After treatment with cisplatin (Sigma-Aldrich, USA), carboplatin (Sigma-Aldrich) or oxaliplatin (Sigma-Aldrich) for 48 h, 10 μL CCK-8 solution (Beyotime Biotechnology, Shanghai, China) was added into the culture medium followed by 2 h incubation at 37°C. Absorbance at 450 nm was then measured by using an ELISA microplate reader. Half maximal inhibitory concentration (IC50) was calculated according to the cell viability curve.

Luciferase Reporter Assay {#s0002-s2005}
-------------------------

The SIRT1 3ʹ-UTR containing the seed regions of the miR-140 binding site (CTGTGGTA) was cloned into the pGL3 Luciferase Reporter Vector (Promega, WI, USA) according to the manufacturer's instruction. The recombinant reporter vector was named as wild SIRT1. The mutant plasmid (mutant SIRT1) was created by mutating the seed region of the miR-140 binding site (CTGTGGTA to CTGACGTA) by using a site-directed mutagenesis kit (Takara). To perform the luciferase reporter assay, cells were co-transfected with the recombinant reporter vector, the pRL-TK Renilla luciferase vector control (Promega) and the miR-140 mimic by using the Lipofectamine 2000. Forty-eight hours after incubation, the luciferase activity was measured by using the Dual-Luciferase Reporter assay system (Promega) according to the manufacturer's instruction. Relative firefly luciferase activity was determined by normalization to renilla luciferase activity in each well.

Western Blot Analysis {#s0002-s2006}
---------------------

Total proteins were extracted by using RIPA buffer (Cell Signaling Technology, Beverly, USA) before separation with 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then transferred to polyvinylidene ﬂuoride (PVDF) membranes (Millipore, Billerica, MA, USA) and probed with specific antibodies of SIRT1, JNK, phosphorylated JNK (p-JNK), cleaved caspase-9, cleaved caspase-3 and GAPDH (Cell Signaling Technology). Blots were then visualized by using enhanced chemiluminescence detection kit (Thermo Fisher Scientific Inc, CA, USA).

Flow Cytometry {#s0002-s2007}
--------------

Cell apoptosis and reactive oxygen species (ROS) levels were detected by flow cytometry analysis. For measurement of apoptotic rate, Annexin V-FITC apoptosis detection kit (Sigma Aldrich) was used to calculate the Annexin V-positive cells. For detection of ROS, cells were stained with dihydroethidium (DHE) (Beyotime Biotechnology) followed by analyzing on flow cytometry according to the manufacturer's instruction.

Statistical Analysis {#s0002-s2008}
--------------------

Experiments were independently repeated at least 3 times to obtain the data. Non-paired *t* test was used to estimate the statistical differences between two groups. One-way analysis of variance (ANOVA) was used to determine the differences between three or more groups. Data were analyzed by using SPSS 16.0 software and *P* value \<0.05 was considered to indicate a statistically significant difference.

Results {#s0003}
=======

Cisplatin-Resistant PC9 and A549 Cells Exhibit Low Level of MiR-140 {#s0003-s2001}
-------------------------------------------------------------------

To study the cisplatin resistance in NSCLC, we established the cisplatin-resistant NSCLC models on PC9 and A549 cell lines. Our data showed that the PC9/R and A549/R cells exhibited obvious resistance to cisplatin treatment compared to their parental PC9 and A549 cells, respectively ([Figure 1A](#f0001){ref-type="fig"}). Specifically, IC50 of cisplatin to PC9/R and A549/R was 7.9 and 9.2 fold higher than that to PC9 and A549 cells, respectively ([Figure 1B](#f0001){ref-type="fig"}). Next, we compared the difference of some cancer-related miRNAs between cisplatin-resistant NSCLC cells and routine NSCLC cells. We found that expression level of miR-140 was significantly reduced in PC9/R and A549/R cell ([Figure 1C](#f0001){ref-type="fig"}). Taken together, we demonstrated that our established cisplatin-resistant NSCLC cells exhibited obvious cisplatin-resistance and low level of miR-140 compared to the routine NSCLC cells.Figure 1Downregulation of miR-140 in PC9/R and A549/R. (**A**) CCK-8 assay was used to test the sensitivity of PC9, PC9/R, A549 and A549/R cells to different concentrations of cisplatin (0\~50 μM). (**B**) IC50 of cisplatin to PC9, PC9/R, A549 and A549/R cells. (**C**) QRT-PCR analysis was used to evaluate the different of miR-140 expression between routine NSCLC cells and cisplatin-resistant NSCLC cells. \**P*\<0.05.

Expression Level of MiR-140 is Associated with Cisplatin-Sensitivity of NSCLC Cells {#s0003-s2002}
-----------------------------------------------------------------------------------

As cytotoxicity of 10 μM cisplatin was slight to PC9/R and A549/R and significant to PC9 and A549 ([Figure 1A](#f0001){ref-type="fig"}), we chose this concentration of cisplatin (10 μM) for the following experiments. To investigate whether downregulation of miR-140 was involved in the chemoresistance of PC9/R and A549/R, we transfected these cells with miR-140 mimic. The transfection efficiency is shown in [Figure 2A](#f0002){ref-type="fig"}. We then found that restore of miR-140 expression in PC9/R and A549/R cells significantly increased their sensitivity to cisplatin treatment ([Figure 2B](#f0002){ref-type="fig"}). Specifically, miR-140 decreased the IC50 of cisplatin to PC9/R and A549/R by 74.2% and 67.7%, respectively ([Figure 2C](#f0002){ref-type="fig"}). On the other hand, to investigate the role of miR-140 in the routine NSCLC cells, we knocked down the miR-140 in PC9 and A549 cells through transfection with anti-miR-140 ([Figure 2D](#f0002){ref-type="fig"}). We then found that reduction of miR-140 expression in PC9 and A549 cells significantly decreased their sensitivity to cisplatin treatment ([Figure 2E](#f0002){ref-type="fig"}). Specifically, anti-miR-140 increased the IC50 of cisplatin to PC9 and A549 by 3.04 fold and 3.66 fold, respectively ([Figure 2F](#f0002){ref-type="fig"}). Taken together, we demonstrated that reduction of miR-140 was responsible for the formation of cisplatin in NSCLC. Furthermore, restore of miR-140 expression can partially reduce the cisplatin resistance of NSCLC.Figure 2Expression of miR-140 partially determined sensitivity of NSCLC cells to cisplatin. (**A**) Transfection efficiency of miR-140 mimic in PC9/R and A549/R was evaluated by qRT-PCR analysis. (**B**) MiR-140 increased the cytotoxicity of cisplatin (10 μM) against PC9/R and A549/R. (**C**) Effect of miR-140 on reducing the IC50 of cisplatin to PC9/R and A549/R. (**D**) Transfection efficiency of anti-miR-140 in PC9 and A549 was evaluated by qRT-PCR analysis. (**E**) Anti-miR-140 decreased the cytotoxicity of cisplatin (10 μM) against PC9 and A549. (**F**) Effect of anti-miR-140 on increasing the IC50 of cisplatin to PC9 and A549. \**P*\<0.05 vs NCO group. ^\#^*P*\<0.05 vs cisplatin+NCO group.

MiR-140 Targets SIRT1 in NSCLC {#s0003-s2003}
------------------------------

To understand how miR-140 prevented the cisplatin resistance of NSCLC, we searched for the potential mRNA targets of miR-140 through TargetScan, miRanda, and PicTar databases. All of these databases showed that 3ʹ- UTR of SIRT1 contained a putative binding sequence paired with miR-140 ([Figure 3A](#f0003){ref-type="fig"}). On the other hand, in contrast to the downregulation of miR-140 in PC9/R and A549/R ([Figure 1C](#f0001){ref-type="fig"}), PC9/R and A549/R cells expressed obviously higher level of SIRT1 at both of the mRNA level ([Figure 3B](#f0003){ref-type="fig"}) and protein level ([Figure 3C](#f0003){ref-type="fig"}). Therefore, we predicted that miR-140 targeted SIRT1 in NSCLC. To confirm the regulation of miR-140 on SIRT1, we compared the expression level of SIRT1 between the miR-140-transfected cells and the control cells. We then found that the expression level of SIRT1 was reduced when the cells overexpressed miR-140 ([Figure 3D](#f0003){ref-type="fig"}). On the other hand, knockdown of miR-140 was found to increase the expression of SIRT1 in PC9 and A549 ([Figure 3E](#f0003){ref-type="fig"}). These results suggested the negative correlation between miR-140 and SIRT1. Furthermore, results of luciferase reporter assays showed that co-transfection with miR-140 significantly decreased the luciferase activity of pGL3 reporters which contained wild type SIRT1 3ʹ-UTR ([Figure 3F](#f0003){ref-type="fig"}). Taken together, these data demonstrated that miR-140 targeted SIRT1 in NSCLC.Figure 3MiR-140 targeted SIRT1 in NSCLC. (**A**) Putative binding sequence of SIRT1 3'-UTR paired with miR-140. (**B**) Cisplatin-resistant NSCLC cells expressed higher level of SIRT1 compared to the routine NSCLC cells at the mRNA level. (**C**) Cisplatin-resistant NSCLC cells expressed higher level of SIRT1 compared to the routine NSCLC cells at the protein level. (**D**) Transfection with miR-140 mimic decreased the expression of SIRT1 in PC9/R and A549/R. (**E**) Transfection with anti-miR-140 increased the expression of SIRT1 in PC9 and A549. (**F**) MiR-140 decreased the luciferase activity of pGL3 reporters which contained wild type SIRT1 3'-UTR. \**P*\<0.05. ^\#^*P*\<0.05 vs NCO group.

Expression Level of SIRT1 is Associated with Cisplatin-Sensitivity of NSCLC Cells {#s0003-s2004}
---------------------------------------------------------------------------------

To investigate whether overexpression of SIRT1 was involved in the formation of drug resistance in NSCLC, we directly overexpressed SIRT1 in PC9 and A549 cells by using SIRT1 plasmid. The transfection efficiency is shown in [Figure 4A](#f0004){ref-type="fig"}. We then found that overexpression of SIRT1 in PC9 and A549 cells significantly decreased their sensitivity to cisplatin treatment ([Figure 4B](#f0004){ref-type="fig"}). It indicated that overexpression of SIRT1 was an important factor that can partially induce cisplatin resistance of NSCLC. On the other hand, to investigate the role of SIRT1 in the cisplatin-resistant NSCLC cells, we knocked down the SIRT1 in PC9/R and A549/R cells through transfection with SIRT1 siRNA ([Figure 4C](#f0004){ref-type="fig"}). We then found that reduction of SIRT1 expression in PC9/R and A549/R cells significantly increased their sensitivity to cisplatin treatment ([Figure 4D](#f0004){ref-type="fig"}). These data indicated that inhibition of SIRT1 can reduce the cisplatin resistance of NSCLC.Figure 4Overexpression of SIRT1 was responsible for the cisplatin resistance of PC9/R and A549/R. (**A**) Transfection efficiency of SIRT1 plasmid in PC9 and A549 was evaluated by Western blot assay. (**B**) SIRT1 plasmid decreased the cytotoxicity of cisplatin (10 μM) against PC9 and A549. (**C**) Transfection efficiency of SIRT1 siRNA in PC9/R and A549/R was evaluated by Western blot assay. (**D**) SIRT1 siRNA increased the cytotoxicity of cisplatin (10 μM) against PC9/R and A549/R. \**P*\<0.05 vs empty plasmid group. ^\#^*P*\<0.05 vs cisplatin+empty plasmid group. ^&^*P*\<0.05 vs control siRNA group. ^\$^*P*\<0.05 vs cisplatin+control siRNA group.

MiR-140 Reduces the Cisplatin Resistance of PC9/R and A549/R Through Suppression of SIRT1 {#s0003-s2005}
-----------------------------------------------------------------------------------------

To explore whether the effect of miR-140 on reducing the cisplatin resistance of PC9/R and A549/R was dependent on the SIRT1 pathway, SIRT1 plasmid was used in the miR-140-transfected PC9/R and A549/R cells. Results of cell viability assay showed that miR-140 significantly increased the cytotoxicity of cisplatin against PC9/R and A549/R. However, enforced expression of SIRT1 increased the cell viability of PC9/R and A549/R cells which were co-treated with cisplatin and miR-140 ([Figure 5A](#f0005){ref-type="fig"}). Specifically, despite miR-140 decreased the IC50 of cisplatin to PC9/R and A549/R, co-transfection with SIRT1 plasmid inhibited the effect of miR-140 ([Figure 5B](#f0005){ref-type="fig"}). Taken together, we demonstrated that miR-140 reduced the cisplatin resistance of PC9/R and A549/R through suppression of SIRT1.Figure 5MiR-140 decreased the cisplatin-resistance of PC9/R and A549/R through inhibition of SIRT1. (**A**) Effect of SIRT1 plasmid on protecting the PC9/R and A549/R cells from the cytotoxicity of co-treatment with cisplatin (10 μM) and miR-140. (**B**) SIRT1 plasmid reduced the effect of miR-140 on decreasing the IC50 of cisplatin to PC9/R and A549/R. \**P*\<0.05 vs NCO group. ^\#^*P*\<0.05 vs cisplatin+NCOgroup. ^&^*P*\<0.05 vs cisplatin+miR-140 group. ^\$^*P*\<0.05 vs miR-140 group.

MiR-140 Enhances Cisplatin-Induced Apoptosis of PC9/R and A549/R Cells Through the SIRT1/ROS Pathway {#s0003-s2006}
----------------------------------------------------------------------------------------------------

As SIRT-1 functions to inhibit the generation of ROS in cells,[@cit0031] we next investigated the association between cisplatin resistance and the miR-140/SIRT1/ROS pathway. As shown in [Figure 6A](#f0006){ref-type="fig"}, cisplatin (10 μM) failed to induce obvious generation of ROS. However, co-treatment with miR-140 promoted the production of ROS through the suppression of SIRT1. Results of Western blot analysis and flow cytometry showed that combination with cisplatin and miR-140 induced significant activation of caspase-9 and caspase-3 ([Figure 6B](#f0006){ref-type="fig"}) and occurrence of apoptosis ([Figure 6C](#f0006){ref-type="fig"}). However, N-acetylcysteine (NAC) which is a potent ROS scavenger[@cit0032] inhibited the caspase-dependent apoptosis of PC9/R and A549/R cells which were co-treated with cisplatin and miR-140 ([Figure 6B](#f0006){ref-type="fig"} and [C](#f0006){ref-type="fig"}). Taken together, these data indicated that miR-140 can enhance the cisplatin-induced apoptosis of PC9/R and A549/R cells through the SIRT1/ROS pathway.Figure 6MiR-140 promoted the cisplatin-induced apoptosis through the ROS pathway. (**A**) Cells which were treated with cisplatin (10 μM), miR-140, SIRT1 plasmid and NAC (2 mM). 48 h later, ROS level of PC9/R and A549/R was evaluated by flow cytometry. (**B**) Western blot analysis was performed to detect the cleavage of caspase-9 and caspase-3 in PC9/R and A549/R cells which were treated with cisplatin (10 μM), miR-140, SIRT1 plasmid and NAC (2 mM). (**C**) Cells which were treated with cisplatin (10 μM), miR-140, SIRT1 plasmid and NAC (2 mM). 48 h later, flow cytometry analysis was performed to detect the apoptotic rate of PC9/R and A549/R cells. \**P*\<0.05 vs cisplatin+NCO group. ^\#^*P*\<0.05 vs cisplatin+miR-140 group.

JNK is the Downstream of ROS Pathway in PC9/R and A549/R {#s0003-s2007}
--------------------------------------------------------

As JNK is a molecular linkage between ROS and cellular apoptosis,[@cit0033] we next investigated the role of JNK in miR-140-promoted cell death. As shown in [Figure 7A](#f0007){ref-type="fig"}, combination treatment with cisplatin and miR-140 induced obvious phosphorylation of JNK. However, phosphorylation of JNK in PC9/R and A549/R can be inhibited by either NAC or SP600125 which is a JNK specific inhibitor.[@cit0034] On the other hand, we showed that SP600125 can not affect the production of ROS in PC9/R and A549/R cells which were co-treated with cisplatin and miR-140 ([Figure 7B](#f0007){ref-type="fig"}). These results indicated that JNK was the downstream of ROS pathway in PC9/R and A549/R. Next, we investigated the role of miR-140/SIRT1/ROS/JNK pathway in cisplatin resistance of PC9/R and A549/R. Results of CCK-8 assay and flow cytometry assay showed that combination treatment with cisplatin and miR-140 induced significant apoptotic cell death of PC9/R and A549/R. However, co-treatment with SIRT1 plasmid, NAC or SP600125 prevented the apoptotic cell death of PC9/R and A549/R ([Figure 7C](#f0007){ref-type="fig"} and [7D](#f0007){ref-type="fig"}). These data indicated that miR-140 targeted the SIRT1/ROS pathway to promote the activation of JNK which was induced by cisplatin.Figure 7Role of ROS/JNK pathway in miR-140-promoted apoptosis. (**A**) Expression level of phosphorylated JNK in PC9/R and A549/R cells which were treated with cisplatin (10 μM), miR-140, SIRT1 plasmid, NAC (2 mM) and SP600125 (50 μM). (**B**) SP600125 (50 μM) failed to change the ROS level in PC9/R and A549/R cells which were co-treated with cisplatin (10 μM) and miR-140 for 48 h. (**C**) Cytotoxicity of co-treatment with cisplatin (10 μM) and miR-140 against PC9/R and A549/R was inhibited by SIRT1 plasmid, NAC (2 mM) and SP600125 (50 μM). (**D**) Apoptotic and necrotic rate of NSCLC cells treated with cisplatin (10 μM), SIRT1 plasmid, NAC (2 mM) and SP600125 (50 μM). Cells were treated for 48 h before detection by flow cytometry. \**P*\<0.05 vs NCO group. ^\#^*P*\<0.05 vs cisplatin+NCO group. ^&^*P*\<0.05 vs cisplatin+miR-140 group.

Activity of MiR-140 on Decreasing the Cross-Resistance of NSCLC Cells to Other Platinum-Based Chemotherapeutic Drugs {#s0003-s2008}
--------------------------------------------------------------------------------------------------------------------

We next investigated the activity of miR-140 on the cross-resistance of NSCLC cells. Analysis of cisplatin IC50 showed that the established cisplatin-resistant NSCLC cell lines PC9/R and A549/R exhibited obvious cross-resistance to carboplatin ([Figure 8A](#f0008){ref-type="fig"}) and oxaliplatin ([Figure 8B](#f0008){ref-type="fig"}). However, we found that transfection with miR-140 can significantly decrease the IC50 of PC9/R and A549/R cells to carboplatin ([Figure 8C](#f0008){ref-type="fig"}) and oxaliplatin ([Figure 8D](#f0008){ref-type="fig"}). On the other hand, we found that knockdown of miR-140 significantly increased the IC50 of PC9 and A549 cells to carboplatin ([Figure 8E](#f0008){ref-type="fig"}) and oxaliplatin ([Figure 8F](#f0008){ref-type="fig"}). Taken together, we demonstrated that miR-140 exhibited activity on decreasing the cross-resistance of NSCLC cells to platinum-based drugs.Figure 8Effect of miR-140 on reversing the cross-resistance of PC9/R and A549/R to carboplatin and oxaliplatin. (**A**) PC9/R and A549/R exhibited cross-resistance to carboplatin. (**B**) PC9/R and A549/R exhibited cross-resistance to oxaliplatin. (**C**) MiR-140 reduced the cross-resistance of carboplatin to PC9/R and A549/R. (**D**) MiR-140 reduced the cross-resistance of oxaliplatin to PC9/R and A549/R. (**E**) Knockdown of miR-140 induced the resistance of carboplatin to PC9 and A549. (**F**) Knockdown of miR-140 induced the resistance of oxaliplatin to PC9 and A549. \**P*\<0.05 vs PC9 group. ^\#^*P*\<0.05 vs A549 group. ^&^*P*\<0.05 vs NCO group.

Discussion {#s0004}
==========

Cisplatin-based chemotherapy is considered as the first-line treatment for NSCLC.[@cit0013],[@cit0014] Despite cisplatin-based chemotherapy is effective, development of drug resistance is a usual incidence during the course of cisplatin treatment.[@cit0015],[@cit0016] It is urgent for us to explore useful approaches to reverse the resistance against cisplatin. Recent studies have demonstrated that combination treatment with some miRNAs is able to reduce the chemoresistance of cancers.[@cit0035]--[@cit0038] Among these miRNAs, miR-140 is reported to function as a tumor suppressor.[@cit0024]--[@cit0026] Furthermore, previous studies have indicated that miR-140 can enhance chemosensitivity of some cancers.[@cit0027]--[@cit0029] Given this, we studied the potential role of miR-140 in reversing the cisplatin resistance of NSCLC. In the present study, we proved that our established cisplatin-resistant NSCLC cells showed significant resistance to cisplatin treatment. We then showed the absence of miR-140 in cisplatin-resistant NSCLC cells. Furthermore, we proved that absence of miR-140 was partially responsible for the formation of cisplatin resistance. On the other hand, we found that restore of miR-140 expression was able to resensitize the cisplatin-resistant NSCLC cells to cisplatin-induced cytotoxicity. Our data demonstrated the effect of miR-140 on reversing the cisplatin resistance of NSCLC.

Silent information regulator 1 (SIRT1) belongs to the sirtuin family and functions as a histone deacetylase.[@cit0039] In cancer cells, high level of SIRT1 increases the expression of superoxide dismutase (SOD) which is a key cellular antioxidant. As a result, SIRT1 decreases the generation of ROS that is a key apoptosis promoter.[@cit0040],[@cit0041] Thus, SIRT1 is a potential oncogene and promotes cancer development. Unfortunately, SIRT1 is usually overexpressed in multiple human cancers.[@cit0042]--[@cit0044] Moreover, overexpression of SIRT1 is reported to be responsible for induction of drug resistance.[@cit0045],[@cit0046] Therefore, SIRT1 has been considered as a potential target for cancer therapy.

We focused on the role of SIRT1 in changing the cisplatin sensitivity of NSCLC, because SIRT1 was the potential target of miR-140 and we observed significant upregulation of SIRT1 in PC9/R and A549/R cells compared to their parental PC9 and A549 cells, respectively. We then proved that direct knockdown of SIRT1 resensitized the PC9/R cells and A549/R cells to cisplatin-induced cytotoxicity. On the contrary, enforced expression of SIRT1 in routine PC9 and A549 induced obvious cisplatin resistance. We showed that overexpression of SIRT1 indeed is an important factor for the formation of cisplatin resistance. Furthermore, we proved that the effect of miR-140 on reducing the cisplatin resistance of NSCLC was dependent on the suppression of SIRT1.

In the downstream pathway of ROS-dependent apoptosis, JNK is a molecular linkage between ROS-induced oxidative stress and cellular apoptosis.[@cit0033],[@cit0047],[@cit0048] In the present study, despite platinum-based treatment provided oxidative stress, it failed to produce high level of ROS because of the overexpression of SIRT1 in our established cisplatin-resistant NSCLC cells. However, we proved that co-treatment with miR-140 inhibited the expression of SIRT1. Therefore, the miR-140-overexpressed PC9/R and A549/R cells produced high level of ROS under the treatment of cisplatin. As a result, the JNK pathway was activated and the cell apoptosis occurred in the cisplatin-resistant NSCLC cells.

In summary, this study indicated the effect of miR-140 on resensitizing cisplatin-resistant NSCLC cells to the treatment of platinum-based drugs. The potential mechanism by which miR-140 reduced the drug resistance was dependent on the SIRT1/ROS/JNK pathway. This study indicated that combination with miR-140 may represent a novel strategy for efficient application of cisplatin in NSCLC treatment.
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